Lastly, pt0045, a 49-year-old woman with metastatic triple-negative breast cancer involving lungs and lymph nodes on second-line treatment with a combination involving an anti-PD1/PD-L1 agent, had 7 somatic mutations present in her baseline plasma sample, with VAF between 2% and 9%. This evidence concerns the gene CD274 and triple-negative breast carcinoma.